Ulcerative Colitis

- TachoSil (Human fibrinogen and human thrombin), Nycomed Austria GmbH, to amend the indication by deleting the following statement: 'Efficacy has only been demonstrated in liver surgery'.

TachoSil was first authorised in the European Union on 8 June 2004 and is approved for supportive treatment in surgery for improvement of haemostasis where standard techniques are insufficient.

The CHMP also recommended the approval of Bondenza (ibandronic acid) and Bonviva (ibandronic acid) 3mg/3ml solution for injection.

Bondenza and Bonviva were first authorised in the European Union on 23 February 2004 and are both indicated for the treatment of osteoporosis.

This strength is for intravenous administration once every 3 months compared to once daily and once monthly oral administrations previously authorised.

Summaries of opinions for all these products are available and can be found here emea.eu.int/htms/human/opinion/opinion.htm.

Re-examination procedure concluded Following the re-examination of the negative opinion adopted on 13 October 2005, the Committee adopted a final positive opinion to recommend the extension of indication for Exelon and Prometax, from Novartis Europharm Ltd, to add the symptomatic treatment of mild to moderately severe dement...

A biochip or DNA-chip simply requires a tiny blood sample from the patient.

The DNA-chip permits prediction of the evolution and prognosis of the disease as well as selection of the most adequate treatment for each individual.

There are more than 100,000 people affected with IBD in Spain, and in 2004, treatment costs of these pathologies amounted to 7,382 Euros per patient, which brings the annual public health cost near to millions of Euros annually.

Progenika Biopharma has presented the IBDchip (Inflammatory Bowel Disease DNA Chip).

This DNA-chip enables an improvement of prognostic and therapeutic management of those patients with IBD.

The DNA-chip was developed in collaboration with Miquel Sans, MD, member of the gastroenterology service of the Hospital Clinic in Barcelona and Carlos Cara, MD, of UCB Pharma.

A multicenter study carried out on more than 500 patients guarantees the precision of this discovery.

At present, the IBD chip analyses 61 polymorphisms related to IBD.

The DNA-chip includes the polymorphisms that until now have been associated with the disease only in scientific reading, the tendency to suffer from it and its possible course, but it is already an open tool, and as new related mutations are identified, they can be incorporated into the IBDchip...